ALKS vs PFE: fair value comparison
Alkermes plc and Pfizer Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. ALKS carries the stronger quality grade.
| ALKS | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $47.20 | $27.72 |
| 12-month range | $28.26–$51.72 | $24.23–$28.55 |
| Sector rank | #112 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | A | D |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ALKS fair value analysis · PFE fair value analysis